Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1181-1187

  Proksch, Joel W ^a   Lowe, Ezra R ^a   Ward, Keith W ^a  

^a BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MAPRACORAT; PREDNISOLONE ACETATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CILIARY BODY; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; HAPLORHINI; IRIS; LACRIMAL FLUID; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RABBIT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BENZOFURANS; CHROMATOGRAPHY, LIQUID; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; FEMALE; MACACA FASCICULARIS; MALE; PENTANOLS; PREDNISOLONE; QUINOLINES; RABBITS; RECEPTORS, GLUCOCORTICOID; TANDEM MASS SPECTROMETRY;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 79959464047     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039099     Document Type: Article

References (30)

1. Augustin AJ, Puls S, and Offermann I (2007) Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 27:133-140.
2. Awan MA, Agarwal PK, Watson DG, McGhee CN, and Dutton GN (2009) Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol 93:708-713.
3. Barza M (1978) Factors affecting the intraocular penetration of antibiotics. The influence of route, inflammation, animal species and tissue pigmentation. Scand J Infect Dis Suppl 14:151-159.
4. Butrus S and Portela R (2005) Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 18:485-492, v.
5. Cavet ME, Harrington KL, Ward KW, and Zhang JZ (2010) Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells. Mol Vis 16:1791-1800.
6. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, and Billson FA (1998) Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 26:277-281. (Pubitemid 28529891)
7. Clark AF, Steely HT, Dickerson JE Jr, English-Wright S, Stropki K, McCartney MD, Jacobson N, Shepard AR, Clark JI, Matsushima H, et al. (2001) Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. Invest Ophthalmol Vis Sci 42:1769-1780. (Pubitemid 32652352)
8. Danis RP, Ciulla TA, Pratt LM, and Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244-250. (Pubitemid 30436775)
9. De Bosscher K, Haegeman G, and Elewaut D (2010) Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 10:497-504.
10. Holland EJ, Bartlett JD, Paterno MR, Usner DW, and Comstock TL (2008) Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 27:50-55.
11. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
12. International Dry Eye WorkShop (2007) Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 5:163-178.
13. James ER (2007) The etiology of steroid cataract. J Ocul Pharmacol Ther 23:403-420.
14. Loteprednol Etabonate US Uveitis Study Group (1999) Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 127:537-544.
15. McCulley JP, Caudle D, Aronowicz JD, and Shine WE (2006) Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 113:955-959. (Pubitemid 43795230)
16. Nieminen T, Lehtimäki T, Mäenpää J, Ropo A, Uusitalo H, and Kähönen M (2007) Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 67:237-245. (Pubitemid 46410612)
17. Palmero M, Bellot JL, Alcoriza N, García-Cabanes C, and Orts A (1999) The ocular pharmacokinetics of topical diclofenac is affected by ocular inflammation. Ophthalmic Res 31:309-316. (Pubitemid 29257443)
18. Pfeffer BA, DeWitt CA, Salvador-Silva M, Cavet ME, López FJ, and Ward KW (2010) Reduced myocilin expression in cultured monkey trabecular meshwork cells induced by a selective glucocorticoid receptor agonist: comparison with steroids. Invest Ophthalmol Vis Sci 51:437-446.
19. Raizman M (1996) Corticosteroid therapy of eye disease. Fifty years later. Arch Ophthalmol 114:1000-1001.
20. Ronacher K, Hadley K, Avenant C, Stubsrud E, Simons SS Jr, Louw A, and Hapgood JP (2009) Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Mol Cell Endocrinol 299:219-231.
21. Roters S, Aspacher F, and Diestelhorst M (1996) The influence of dexamethasone 0.1% eye drops on plasma cortisol and ACTH concentrations after cataract surgery. Ophthalmologica 210:211-214. (Pubitemid 26226398)
22. Salminen L (1990) Review: Systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol 6:243-249.
23. Schäcke H, Berger M, Rehwinkel H, and Asadullah K (2007) Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275:109-117. (Pubitemid 47259282)
24. Schäcke H, Döcke WD, and Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23-43.
25. Schäcke H and Rehwinkel H (2004) Dissociated glucocorticoid receptor ligands. Curr Opin Investig Drugs 5:524-528.
26. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, and Asadullah K (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101:227-232. (Pubitemid 38084232)
27. Schäcke H, Zollner TM, Döcke WD, Rehwinkel H, Jaroch S, Skuballa W, Neuhaus R, May E, Zügel U, and Asadullah K (2009) Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 158:1088-1103.
28. Schwartz SG and Flynn HW Jr (2007) Pharmacotherapies for diabetic retinopathy: present and future. Exp Diabetes Res 2007:52487.
29. Shafiee A, Bucolo C, Budzynski E, Ward KW, and López FJ (2011) In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci 52:1422-1430.
30. Zhang JZ, Cavet ME, VanderMeid KR, Salvador-Silva M, Löpez FJ, and Ward KW (2009) BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells. Mol Vis 15:2606-2616.